TrialNeuro-oncology2010

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

Mark R Gilbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.